Abstract 4791: OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models
Libouban, Marion, Jovcehva, Eleonora, Lange, Desiree De, Janssens, Boudewijn, Verhulst, Tinne, Ogata, Souichi, Wroblowski, Berthold, Mevellec, Laurence, Lu, Tianbao, Clack, Glen, Perera, Timothy
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Published in Cancer research (Chicago, Ill.) (01.07.2018)
Get full text
Journal Article